Jury Rules Roche Infringes Amgen's EPO Patents
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Oct. 23, 2007--Amgen
(NASDAQ:AMGN) announced today that a jury in the U.S. Federal District
Court in Boston ruled that Roche's pegylated-erythropoietin (peg-EPO)
product MIRCERA infringes 11 Amgen EPO patent claims.
Amgen is pleased with the jury's verdict and will now seek an
injunction to prevent Roche from commercializing its peg-EPO product
in the United States in violation of Amgen's affirmed patent rights.
The injunction hearing is scheduled for Nov. 15, 2007.
In addition to infringing its EPO patents, Amgen firmly believes
Roche's peg-EPO product provides no clinical or patient benefit over
Amgen's innovative therapies, EPOGEN(R) (Epoetin alfa) and Aranesp(R)
Amgen remains committed to investing in innovative research and to
delivering medicines that treat grievous illness and meet unmet
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science's promise by bringing safe
and effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis and other serious illnesses. With
a deep and broad pipeline of potential new medicines, Amgen remains
committed to advancing science to dramatically improve people's lives.
To learn more about our pioneering science and our vital medicines,
CONTACT: Amgen, Thousand Oaks
David Polk, 805-447-4613 (media)
Dan Whelan, 805-447-5995 (media)
Arvind Sood, 805-447-1060 (investors)